Cost of managing women presenting with stage IV breast cancer in the United Kingdom

British Journal of Cancer

Volumn 91, Issue 1, 2004, Pages 77-83

  Remak E ^a   Brazil, L ^b  

^a MEDTAP International Inc   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cost of illness; Economic burden; Incidence; Metastatic breast cancer; Stage IV breast cancer

Indexed keywords

AWARENESS; BREAST CANCER; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; COST BENEFIT ANALYSIS; COST CONTROL; DISEASE COURSE; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SURVIVAL TIME; UNITED KINGDOM; ARTICLE; BREAST TUMOR; CLINICAL PRACTICE; COST OF ILLNESS; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE COST; INCIDENCE; METASTASIS; PATHOLOGY; REGISTER; STATISTICS;

BREAST NEOPLASMS; COST OF ILLNESS; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH CARE SURVEYS; HUMANS; INCIDENCE; NEOPLASM METASTASIS; PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES;

EID: 3342971378     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601890     Document Type: Review

References (26)

1. American Cancer Society (2003) Cancer reference information: how is breast cancer staged?. http://www.cancer.org
2. Blum JL (2001) The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer. Oncologist 6: 56-64
3. Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18: 3748-3757
4. British Medical Association and Royal Pharmaceutical Society of Great Britain (2000) Br Natl Formulary, http://www.bnf.org September 2000
5. CancerBACUP (2003) CancerBACUP calls for action over dramatic new evidence of postcode prescribing. http://www.cancerbacup.org.uk/fund/press/ press_16Oct2003.htm
6. Cancer Research UK (2002) CancerStats-Mortality-UK. London, England http://www.cancerresearchuk.org/statistics
7. Dolan P, Torgerson DJ, Wolstenholme J (1999) Costs of breast cancer treatment in the United Kingdom. The Breast 8: 205-207
8. Drummond M (1992) Cost-of-illness studies: a major headache? Pharmacoeconomics 2: 1-4
9. Durr HR, Muller PE, Lenz T, Baur A, Jansson V, Refior HJ (2002) Surgical treatment of bone metastases in patients with breast cancer. Clin Orthop 396: 191-196
10. Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J (1999) Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 56: 67-78
11. Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Perez JE, Machiavelli M, Rodriguez R, Alvarez LA (1988) Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. The GOCS (Grupo Oncologico Cooperative del Sur) experience. Am J Clin Oncol 11: 618-622
12. MEDTAP Database of International Unit Costs (2001) MEDTAP International, Inc, http://www.medtap.com/Products/unitcost.cfm
13. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19: 2596-2606
14. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18: 3758-3767
15. National Institute for Clinical Excellence (NICE) (2001) Guidance on the Use of Taxanes for the Treatment of Breast Cancer. London, England: NICE, Technology Appraisal Guidance no. 30
16. National Institute for Clinical Excellence (NICE) (2002a) Guidance on the Use of Trastuzumab for the Treatment of Advanced Breast Cancer. London, England: NICE, Technology Appraisal Guidance no. 34
17. National Institute for Clinical Excellence (NICE) (2002b) Guidance on the Use of Vinoralbine for the Treatment of Advanced Breast Cancer. London, England: NICE, Technology Appraisal Guidance no. 54
18. National Institute for Clinical Excellence (NICE) (2003) Guidance on the Use of Capecitabine for the Treatment of Locally Advanced or Metastatic Breast Cancer. London, England: NICE, Technology Appraisal Guidance no. 62
19. Nomura Y (1998) Different survival determinants of metastatic breast cancer patients treated with endocrine therapy or chemo-endocrine therapy. Int J Oncol 12: 817-824
20. Office for National Statistics (2001) Cancer Trends in England and Wales 1950-1999. London, England: Office for National Statistics http://www. statistics.gov.uk/downloads/theme_health/cancertrends_5099.pdf
21. Office for National Statistics (2002) Cancer Statistics Registrations: Registrations of Cancer Diagnosed in 1998: Series MB1 no. 29. London, England: Office for National Statistics http://www.statistics.gov.uk/downloads/ theme_health/MB1_No29/MB1_No29.pdf
22. Perez JE, Machiavelli M, Leone BA, Romero A, Rabinovich MG, Vallejo CT, Bianco A, Rodriguez R, Cuevas MA, Alvarez LA (1990) Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncologico Cooperativo del Sur. Am J Clin Oncol 13: 294-298
23. Personal Social Services Research Unit (PSSRU) (2001) Unit costs of health and social care 2001, Netten A, Rees T, Harrison G (eds). Canterbury: The University of Kent at Canterbury
24. Richards MA, Braysher S, Gregory WM, Rubens RD (1993) Advanced breast cancer: use of resources and cost implications. Br J Cancer 67: 856-860
25. Scottish Cancer Registry (1998) Information and Statistics Division (ISD), Common Services Agency for NHS. Edinburgh, Scotland: Scottish Cancer Registry http://www.show.scot.nhs.uk/isd/cancer/cancer.htm
26. Wolstenholme JL, Smith SJ, Whynes DK (1998) The costs of treating breast cancer in the United Kingdom: implications for screening. Int J Technol Assess Health Care 14: 277-289